Mastocytosis Clinical Trial
Official title:
Assessment of Personal, Psychosocial, Work, and Economic Burden in Patients With Mast Cell Disorders,
The symptoms caused by mast cell disorders can have a significant impact on the state of health of individuals, constituting a real burden for them, and consequently altering their quality of life. It therefore seems important to clarify the impact on the quality of life, on the psycho-affective sphere, on professional life and on the direct and indirect costs caused by the disease, as well as on the "patient's remaining burden". It seems possible by a longitudinal study (patient follow-up over 1 year). Primary objective is Assessment of quality of life in adult patient with mast cell diseases at M0.
Mast cell activation symptoms are due to the release of mast cell mediators after uncontrolled activation of mast cells. The release by mast cells of mast cell mediators (tryptase, histamine, prostaglandins, serotonin) results in mast cell activation symptoms, found in mast cell activation syndrome but also in mastocytosis. These symptoms interested the skin, gastrointestinal gut, pulmonary, cardiovascular and neuropsychiatric organs, etc. In mastocytosis, along with these symptoms of mast cell activation, the infiltration of different organs by abnormal mast cells produces many clinical signs related to the excess of monoclonal mast cells present in the organs. According to our clinical experience, the impact of mast cell disorder on various dimensions of life, including economic life, seems important, but it has never accurately evaluated. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01333293 -
The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients
|
Phase 2/Phase 3 | |
| Completed |
NCT01481909 -
Study on Mastocytosis for Rupatadine Treatment
|
Phase 2/Phase 3 | |
| Recruiting |
NCT00044122 -
Study of Factors Regulating Mast Cell Proliferation
|
||
| Recruiting |
NCT06440148 -
Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis
|
||
| Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
| Not yet recruiting |
NCT05084872 -
Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients
|
Phase 2/Phase 3 | |
| Terminated |
NCT01701843 -
Cromoglicate in Mastocytosis
|
Phase 2 | |
| Completed |
NCT00831974 -
Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis
|
Phase 2 | |
| Completed |
NCT00047918 -
Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing
|
N/A | |
| Completed |
NCT00006413 -
Stem Cell Transplantation to Treat Systemic Mastocytosis
|
Phase 2 | |
| Completed |
NCT00050193 -
Cause and Natural Course of Pediatric-Onset Mastocytosis
|
||
| Completed |
NCT02620254 -
Mast Cell Connect: A Registry for Patients With Mastocytosis
|
||
| Completed |
NCT00255346 -
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
|
Phase 2 | |
| Completed |
NCT00001356 -
Characteristics of Mast Cells in Mastocytosis
|
N/A | |
| Recruiting |
NCT06466889 -
Mastocytosis Registry (of Zurich)
|
||
| Recruiting |
NCT05186753 -
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
|
Phase 2 | |
| Completed |
NCT02478957 -
Treatment of Indolent Systemic Mastocytosis With PA101
|
Phase 2 | |
| Recruiting |
NCT02450396 -
Pregnancy and Medically Assisted Conception in Rare Diseases
|
||
| Completed |
NCT00038675 -
Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
|
N/A | |
| Not yet recruiting |
NCT06432556 -
Study of Cellular Heterogeneity in Patients With Mastocytosis
|
N/A |